Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2010 - 2026)

Jazz Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 3.9% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 3.9% YoY), while the FY2025 annual figure was $1.0 billion, up 13.53% from the prior year.
• Accumulated Expenses was $1.0 billion for Q1 2026 at Jazz Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.1 billion in Q1 2025 to a low of $593.2 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $828.7 million across 5 years, with a median of $803.3 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses surged 61.67% in 2022, then retreated 3.9% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $803.3 million in 2022, then declined by 1.16% to $793.9 million in 2023, then advanced by 14.74% to $910.9 million in 2024, then grew by 13.53% to $1.0 billion in 2025, then fell by 1.14% to $1.0 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.